名稱 | TFG-NTRK1/BaF3 |
型號(hào) | CBP73193 |
報(bào)價(jià) | ![]() |
特點(diǎn) | TFG-NTRK1/BaF3,母細(xì)胞:BaF3,凍存條件:90% FBS+10% DMSO; |
產(chǎn)品搜索
相關(guān)文章
- Western Blot標(biāo)準(zhǔn)操作流程
- 細(xì)胞株定期維護(hù)與監(jiān)測(cè)要做好哪些?
- 肺癌靶向治療:腫瘤不進(jìn)展時(shí)間超2年
- Z常用細(xì)胞系之top 5!
- 腫瘤細(xì)胞的信息系統(tǒng)的改變特征大揭秘
- 人結(jié)腸癌細(xì)胞株試驗(yàn)要點(diǎn)及說(shuō)明
- 三陰性乳腺癌的一個(gè)突破口——BRCA基因檢測(cè)?
- PLoS ONE:科學(xué)家發(fā)現(xiàn)癌癥轉(zhuǎn)移的新線索
- CYP1A1基因多態(tài)性用藥指導(dǎo)標(biāo)準(zhǔn)品
- 【連載-企業(yè)參考品】 神經(jīng)膠質(zhì)瘤的診斷參考品的選擇
聯(lián)系我們
電話:4008750250
號(hào)碼:
手機(jī):18066071954
地址:南京市棲霞區(qū)緯地路9號(hào)
Email: zhangxiangwen@cobioer.com
產(chǎn)品展示 / PRODUCTS
藥靶細(xì)胞株 > kinase激酶細(xì)胞株 > CBP73193TFG-NTRK1/BaF3
![TFG-NTRK1/BaF3](http://img80.chem17.com/gxhpic_a89b1029a6/fd9c5b6de14e75b1eafd7ea18ebce581b3ffb67da0e34310505290994c621a9eb8eec7d9fa03e8d2.jpg)
- 詳細(xì)內(nèi)容
CBP73193 | |
I. Introduction | |
Cell Line Name: | TFG-NTRK1/BaF3 |
Host Cell: | Ba/F3 |
Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
Application: | Anti-proliferation assay and PD assay |
Freeze Medium: | 90% FBS+10% DMSO |
Complete Culture Medium: | RPMI-1640+10% FBS+1 ug/ml puromycin |
Mycoplasma Status: | Negative |
II.Background | |
NTRK1 rearrangements involve the kinase domain of the NTRK1 gene which includes 17 exons located on chromosome 1q21-22 (Alberti et al. 2003). The frequency of NTRK1 fusions in patients with adenocarcinoma histology is 3.3% of cases (3 out of 91 patients; Vaishnavi et al. 2013). a In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by ARRY-470, a TRKA/B/C inhibitor (Vaishnavi et al. 2013). b In preclinical studies, cell lines expressing MPRIP-NTRK1 or CD74-NTRK1 were inhibited by lestaurtinib, a FLT3/TRKA inhibitor (Vaishnavi et al. 2013). c A patient with non-small cell lung cancer harboring an MPRIP-NTRK1 fusion mutation was treated with crizotinib, which has activity against TRKA in addition to ALK, MET and ROS1 (Vaishnavi et al. 2013). The patient demonstrated a small radiographic decrease in tumor size but experienced disease progression after three months (Vaishnavi et al. 2013) | |
III. Representative Data | |
1. WB of TFG-NTRK1/BaF3 expression | |
![]() | |
2. Anti-proliferation assay | |
![]() | |
Figure 2. Anti-proliferation assay of two reference compounds on the TFG-NTRK1/BaF3 Stable Cell Line |